Boston Scientific Secures New Credit Facilities for Acquisition

An announcement from Boston Scientific ( (BSX) ) is now available.

On February 26, 2026, Boston Scientific entered into a new $3 billion five-year revolving credit facility maturing in 2031, replacing its 2021 revolver and setting leverage covenants that allow higher temporary gearing following large acquisitions, while excluding specified non-cash charges and capped litigation payments from EBITDA. The company also signed a separate $2 billion 364-day revolving facility and a $6 billion 364-day delayed-draw term loan structure with Wells Fargo as agent, all designed primarily to finance its pending acquisition of Penumbra, Inc., underscoring an aggressive yet covenant-governed funding strategy that could materially increase short-term leverage as it pursues portfolio expansion.

The 364-day revolver and term loans are available to be drawn around the Penumbra closing date, carry interest margins and fees tied to Boston Scientific’s long-term credit ratings, and require prepayment of Tranche B term debt with proceeds from future equity or debt issuance. Collectively, these 2026 credit agreements enhance the company’s liquidity and acquisition firepower while embedding standard events of default and lender protections, signaling lender confidence but committing Boston Scientific to disciplined deleveraging after the Penumbra transaction closes.

The most recent analyst rating on (BSX) stock is a Buy with a $83.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.

Spark’s Take on BSX Stock

According to Spark, TipRanks’ AI Analyst, BSX is a Outperform.

Strong fundamentals and an upbeat outlook (double-digit 2026 growth guidance, margin expansion, and higher expected free cash flow) are the main positives. The score is held back by clearly bearish technicals (price below all major moving averages) and a premium valuation (P/E ~39), which increase sensitivity to any operational or competitive setbacks.

To see Spark’s full report on BSX stock, click here.

More about Boston Scientific

Boston Scientific Corporation is a global medical device manufacturer that develops and markets minimally invasive products for a range of interventional medical specialties, including cardiology, endoscopy and neuromodulation. The company competes in highly regulated healthcare markets where access to flexible, large-scale financing is critical to fund acquisitions, innovation and expansion of its product portfolio.

Average Trading Volume: 13,677,689

Technical Sentiment Signal: Hold

Current Market Cap: $111.5B

For detailed information about BSX stock, go to TipRanks’ Stock Analysis page.